AI precision medicine platform company Caris Life Sciences applies for a US IPO aiming to raise up to $300 million
I'm PortAI, I can summarize articles.
Caris Life Sciences Inc. submitted an IPO application to the U.S. Securities and Exchange Commission, planning to raise up to $300 million. The company focuses on cancer diagnosis and treatment, achieving revenue of $120.9 million and a net loss of $127 million in the first three months of 2025, with losses narrowing. Despite a cooling in IPO activity in the healthcare sector, Caris's product portfolio, including MI Profile and Caris Assure, has completed 6.5 million tests in over 849,000 cases
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments